Nontuberculous Mycobacterial Pulmonary Disease
Conditions
Keywords
Nontuberculous mycobacteria, pulmonary, cohort
Brief summary
Background: NTM(Nontuberculous mycobacteria) pulmonary disease is increasing worldwidely, however the diagnosis and treatment of NTM pulmonary disease still has multiple obstacles. The initiation of treatment is not necessary for all patients with NTM pulmonary disease. In addition, the drugs for treatment of NTM pulmonary disease is not enough. objective. The aim of this prospective registry for Nontuberculous mycobacterial pulmonary disease is to register the NTM pulmonary patients and analysis of the treatment outcome based on the species and to collect the blood and urine samples from the patients for exploring the biomarker for diagnosis and monitoring the NTM pulmonary disease and collect the nontuberculous mycobacterium. Methods: 1. informed consents 2. register in cohort and collect the clinical information and serum, plasma, urine and mycobacteria 3. follow up 6 months to 1year based on the clinical situation Analysis: 1. treatment outcome based on NTM-NET consensus statement 2. exploration of biomarker for progression and monitoring of treatment response
Interventions
None listed
Sponsors
Yonsei University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. age 20 or more than 20 years 2. diagnosed by ATS criteria for NTM pulmonary disease
Exclusion criteria
1\) not specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| treatment outcome based on NTM-NET consensus statement | At the end of the treatment or 12months after treatment | 1. For patients who need the treatment for NTM pulmonary disease : treatment outcome based on the NTM -NET consensus : microbiologic results, clinical symptoms and radiologic results 2. For patients who don't need the treatment for NTM pulmonary disease : progression of NTM-PD defined by clinical, microbiotic and radiologic results. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| biomarker for disease progression: RNA sequence analysis | at the beginning of the treatment | exploration for various biomarkers with RNA sequence analysis |
| biomarker for disease progression: metabolomic analysis | at the beginning of the treatment | exploration for various biomarkers with metabolomic analysis |
| biomarker for monitoring of treatment response: RNA sequence analysis | at the beginning of the treatment | exploration for various biomarkers with RNA sequence analysis |
| biomarker for monitoring of treatment response: metabolomic analysis | at the beginning of the treatment | exploration for various biomarkers with metabolomic analysis |
Countries
South Korea
Outcome results
None listed